245 related articles for article (PubMed ID: 30182761)
1. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B
Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761
[TBL] [Abstract][Full Text] [Related]
2. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.
Akinci B; Koseoglu FD; Onay H; Yavuz S; Altay C; Simsir IY; Ozisik S; Demir L; Korkut M; Yilmaz N; Ozen S; Akinci G; Atik T; Calan M; Secil M; Comlekci A; Demir T
Metabolism; 2015 Sep; 64(9):1086-95. PubMed ID: 26139569
[TBL] [Abstract][Full Text] [Related]
3. Complications of lipodystrophy syndromes.
Akinci G; Celik M; Akinci B
Presse Med; 2021 Nov; 50(3):104085. PubMed ID: 34728268
[TBL] [Abstract][Full Text] [Related]
4. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
Abulizi A; Perry RJ; Camporez JPG; Jurczak MJ; Petersen KF; Aspichueta P; Shulman GI
FASEB J; 2017 Jul; 31(7):2916-2924. PubMed ID: 28330852
[TBL] [Abstract][Full Text] [Related]
5. Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy.
Simha V
Expert Rev Endocrinol Metab; 2014 May; 9(3):205-212. PubMed ID: 30736159
[TBL] [Abstract][Full Text] [Related]
6. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
8. Lipodystrophy for the Diabetologist-What to Look For.
Patni N; Garg A
Curr Diab Rep; 2022 Sep; 22(9):461-470. PubMed ID: 35821558
[TBL] [Abstract][Full Text] [Related]
9. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
[TBL] [Abstract][Full Text] [Related]
10. Lipodystrophies-Disorders of the Fatty Tissue.
Knebel B; Müller-Wieland D; Kotzka J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233602
[TBL] [Abstract][Full Text] [Related]
11. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature.
Misra A; Peethambaram A; Garg A
Medicine (Baltimore); 2004 Jan; 83(1):18-34. PubMed ID: 14747765
[TBL] [Abstract][Full Text] [Related]
13. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia.
Goldenberg NM; Wang P; Glueck CJ
Clin Chim Acta; 2003 Jun; 332(1-2):11-9. PubMed ID: 12763274
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.
Misra A; Garg A
Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189
[TBL] [Abstract][Full Text] [Related]
16. Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People.
Özen S; Akıncı B; Oral EA
J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):17-28. PubMed ID: 31434462
[TBL] [Abstract][Full Text] [Related]
17. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
18. Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature.
Hosokawa M; Shibata H; Hosokawa T; Irie J; Ito H; Hasegawa T
J Pediatr Endocrinol Metab; 2019 May; 32(5):537-541. PubMed ID: 31075084
[TBL] [Abstract][Full Text] [Related]
19. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
